184 related articles for article (PubMed ID: 7532031)
1. Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase.
Im T; Yamane T; Mugitani A; Hiyoshi M; Park K; Tatsumi N
Int J Hematol; 1994 Oct; 60(3):215-23. PubMed ID: 7532031
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
[TBL] [Abstract][Full Text] [Related]
3. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
4. Clinical effects of recombinant human granulocyte colony-stimulating factor in leukemia patients: a phase I/II study.
Teshima H; Ishikawa J; Kitayama H; Yamagami T; Hiraoka A; Nakamura H; Shibata H; Masaoka T; Takaku F
Exp Hematol; 1989 Sep; 17(8):853-8. PubMed ID: 2475358
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
[TBL] [Abstract][Full Text] [Related]
6. [Trial of combined cytosine arabinoside with granulocyte colony-stimulating factor therapy or refractory acute myeloid leukemia].
Mori H; Kuriyama K; Tawara M; Danno Y; Fujimoto K; Tushima H; Saito M; Yamamura M; Hata T; Arimura M
Rinsho Ketsueki; 1995 Jul; 36(7):648-56. PubMed ID: 7563592
[TBL] [Abstract][Full Text] [Related]
7. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
[TBL] [Abstract][Full Text] [Related]
8. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study of rhG-CSF (KRN8601) in patients with myelodysplastic syndrome].
Toyama K; Ohyashiki J; Takaku F; Kobayashi Y; Miyazono K; Miura Y; Sakamoto S; Mizoguchi H; Hoshino S; Urabe A
Rinsho Ketsueki; 1990 Jul; 31(7):937-45. PubMed ID: 1699007
[TBL] [Abstract][Full Text] [Related]
10. Sequential promotion of normal and leukemic hemopoiesis by recombinant human granulocyte colony-stimulating factor during the course of myelodysplastic syndrome.
Ueda T; Kawai Y; Sugiyama T; Takeuchi N; Yoshida A; Iwasaki H; Wano Y; Tsutani H; Kamada N; Nakamura T
Int J Hematol; 1993 Dec; 59(1):47-52. PubMed ID: 7512833
[TBL] [Abstract][Full Text] [Related]
11. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
[TBL] [Abstract][Full Text] [Related]
13. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
15. [Mobilization of autologous peripheral blood stem cells by cytosine arabinoside combined with recombinant human granulocyte colony-stimulating factor].
Shi Y; Han X; He X; Yang J; Liu P
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(7):462-6. PubMed ID: 12133516
[TBL] [Abstract][Full Text] [Related]
16. [Differentiation therapy for myelodysplastic syndrome].
Hino K; Nakamaki T
Rinsho Ketsueki; 1993 Mar; 34(3):283-8. PubMed ID: 7683064
[TBL] [Abstract][Full Text] [Related]
17. [Complete remission achieved by low-dose Ara-C, aclarubicin and rhG-CSF (CAG) therapy in acute non-lymphocytic leukemia with monosomy 7 occurring after severe aplastic anemia].
Yamato H; Yamada K; Koike T; Yoshida M; Tsunogake S; Aoyagi M; Nakamura Y; Watanabe K; Saito K; Enokihara H
Rinsho Ketsueki; 1995 Feb; 36(2):128-33. PubMed ID: 7536277
[TBL] [Abstract][Full Text] [Related]
18. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.
Mori T; Aisa Y; Yokoyama A; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Kato J; Watanabe R; Takayama N; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2007 Feb; 39(4):217-21. PubMed ID: 17220902
[TBL] [Abstract][Full Text] [Related]
19. [Effect of low-dose Ara-C in the treatment of refractory, atypical leukemia and myelodysplastic syndrome].
Tsubaki K; Horiuchi A; Nagai K; Kanamaru A; Kohsaki M; Kitani T; Tagawa S; Masaoka T; Shibata H; Yasunaga K
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):996-1003. PubMed ID: 3457553
[TBL] [Abstract][Full Text] [Related]
20. Treatment of acute nonlymphocytic leukemia by combination of recombinant human granulocyte colony-stimulating factor and cytotoxic agents: a report of six cases.
Hanazono Y; Miyazono K; Piao YF; Taketazu F; Chiba S; Miyagawa K; Hirai H; Sakamoto S; Miura Y; Yazaki Y
Int J Hematol; 1992 Jun; 55(3):243-8. PubMed ID: 1379844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
